Abstract:The abscopal effect is defined as tumor regression seen at sites distant from the irradiated tissue. We aimed to observe the abscopal effects in patients diagnosed with recurrent or refractory advanced thymic epithelial tumors by treating with granulocyte-macrophage colony-stimulating factor (GM-CSF) and radiotherapy. In this retrospective serial, thymic epithelial tumor patients with at least three distinct measurable sites of disease, treated with concurrent radiotherapy (35 Gy in ten fractions or 30 Gy in ten fractions, over 2 weeks) to one metastatic site and GM-CSF (125 μg/m2 subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy), were recruited. The course was repeated, targeting a second metastatic site. No systemic treatment was applied. The primary endpoint was the proportion of patients with an abscopal response (estimated using investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1) and the secondary endpoint was toxicity and progression free survival (PFS). From April 12, 2016, to Sep 9, 2019, 12 patients were enrolled. One patient was excluded because of histologically confirmed with small cell malignant tumor. Another thymic carcinoma patient who developed heart injury during treatment and did not complete scheduled therapy was then only evaluable for toxicity. Among ten patients who were eligible for efficacy evaluation, there were three with thymic squamous cell carcinoma, one with type B1, three with type B2 and three with type B3 thymoma, respectively. Four patients had Masaoka-Koga stage IVa diseases and six had stage IVb diseases. The median follow-up time was 17 months (Interquartile Range = 10, 23). The abscopal response was observed in 3 out of 10 patients (30%) with 2 partial responses (one thymic carcinoma and one type B1 thymoma) and 1 complete response (type B3 thymoma). Five patients with malignant thymoma were assessed as stable disease as their best response. Two patients with thymic carcinoma suffered from disease progression. The median PFS was 25 months for abscopal responders. 1-year PFS rate was 100% for abscopal responders while the value was 55.6% for non-responders (p = 0.21). Four patients had grade 3 adverse events (heart injury, anemia, leucopenia and neutropenia). The most common grade 2 adverse events were leucopenia (three patients). Myasthenia gravis (grade 2) was observed in one patient. The combination GM-CSF and local radiotherapy alone generated clear abscopal effects in patients with recurrent or refractory advanced thymic epithelial tumors.

Abscopal Effect after Stereotactic Body Radiotherapy with Nivolumab for Lung Metastasis of Head and Neck Cancer: A Case Report

Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review

Abscopal effect following checkpoint inhibitor therapy and localized radiotherapy for metastatic clear cell renal cell carcinoma: A case report

Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy

Systemic Effects of Radiation Therapy-Induced Abscopal Responses in Patients with Advanced Lung Cancer

Abscopal Effect of Stereotactic Radiotherapy Combined with Anti‐pd‐1/pd‐l1 Immunotherapy: Mechanisms, Clinical Efficacy, and Issues

Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report

[Abscopal effect: Myth or reality?]

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.

Nanotechnology-enhanced radiotherapy and the abscopal effect: Current status and challenges of nanomaterial-based radio-immunotherapy

Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature

Using immunotherapy to boost the abscopal effect

Recent Research Progress of Abscopal Effect in Tumor Radiotherapy

Killing two birds with one stone: Abscopal Effect Mechanism and its application prospect in radiotherapy

Abscopal Effects Induced by Radiotherapy Combined with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Recurrent or Refractory Metastatic Thymic Epithelial Tumors: A Single-Institution Experience

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

A good response to anti-PD-1 monoclonal antibody plus SBRT in a patient with PD-L1-negative recurrent advanced esophageal cancer: a long-term follow-up case report of a possible abscopal effect

Bystander Effect and Abscopal Effect in Recurrent Thymic Carcinoma Treated with Carbon-Ion Radiation Therapy: A Case Report

Effect of Low-Dose Radiotherapy on Abscopal Responses to Hypofractionated Radiotherapy and Anti-Pd1 in Mice and NSCLC Patients.

Abscopal effect-induced spontaneous regression of distant metastases in malignant mesenchymal tumor: a case report

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer